BioPharma Dive September 18, 2025
The purchase gives Biogen full access to an implantable device designed to help patients avoid the repeat lumbar punctures required for medicines like Spinraza.
Dive Brief:
- Biogen is buying Alcyone Therapeutics after working with the company for more than two years on a better delivery system for neurological medicines built around antisense oligonucleotides.
- Under terms announced Thursday, Biogen will spend $85 million upfront to acquire the privately held company and promise additional payments to Alcyone investors if certain development and regulatory goals are reached. Biogen will gain all rights to ThecaFlex DRx, an implantable subcutaneous port and catheter device it’s been developing with Alcyone since 2023.
- The companies have two studies underway testing the system’s delivery of Biogen’s Spinraza...
Today's Sponsors
Today's Sponsor